The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

New driver mutations in non-small-cell lung cancer - The Lancet Oncology

LC-SCRUMによる新規非小細胞肺癌ドライバーの同定／ゲノム編集による治療を臓器特異的，病態特異的に届ける／コロナワクチン免疫の経時的な減衰

ROS1-dependent cancers - biology, diagnostics and therapeutics

The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. - Abstract - Europe PMC

Frontiers Recent progress in targeted therapy for non-small cell lung cancer

Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities

Expression of LTK constructs in 293T cells. (A) Relative protein

PDF] Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients

Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusions

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

PDF) ALK, ROS1, RET and NTRK1–3 Gene Fusions in Colorectal and Non-Colorectal Microsatellite-Unstable Cancers

Review: biological implications of oncogenic rearrangements in non-small cell lung cancer - Di Marco - Precision Cancer Medicine

AMG-510 and cisplatin combination increases antitumor effect in lung adenocarcinoma with mutation of KRAS G12C: a preclinical and translational research